Crawford Investment Counsel Inc. Sells 96,714 Shares of Perrigo Company plc $PRGO

Crawford Investment Counsel Inc. trimmed its position in Perrigo Company plc (NYSE:PRGO) by 7.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,177,753 shares of the company’s stock after selling 96,714 shares during the period. Crawford Investment Counsel Inc. owned 0.86% of Perrigo worth $16,394,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Amundi lifted its stake in shares of Perrigo by 11.7% in the 1st quarter. Amundi now owns 5,292 shares of the company’s stock valued at $148,000 after acquiring an additional 556 shares during the last quarter. Kestra Investment Management LLC lifted its stake in shares of Perrigo by 57.1% in the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock valued at $47,000 after acquiring an additional 642 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after acquiring an additional 786 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in shares of Perrigo by 89.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,778 shares of the company’s stock valued at $38,000 after acquiring an additional 838 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Perrigo by 116.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,888 shares of the company’s stock valued at $26,000 after acquiring an additional 1,014 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors.

Perrigo Stock Down 0.4%

Shares of NYSE:PRGO opened at $10.66 on Wednesday. The firm has a market cap of $1.47 billion, a P/E ratio of -0.81, a P/E/G ratio of 1.27 and a beta of 0.51. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. Perrigo Company plc has a 12-month low of $9.23 and a 12-month high of $28.43. The business has a fifty day simple moving average of $11.18 and a 200 day simple moving average of $12.41.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The business had revenue of $841.80 million during the quarter, compared to analyst estimates of $1.04 billion. During the same period last year, the company earned $0.60 EPS. Perrigo’s revenue for the quarter was down 7.2% compared to the same quarter last year. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts predict that Perrigo Company plc will post 2.11 earnings per share for the current year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Friday, May 29th were issued a dividend of $0.29 per share. This represents a $1.16 dividend on an annualized basis and a yield of 10.9%. The ex-dividend date was Friday, May 29th. Perrigo’s dividend payout ratio (DPR) is presently -8.85%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings upgraded Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Jefferies Financial Group reaffirmed a “hold” rating on shares of Perrigo in a research report on Thursday, February 26th. Zacks Research raised Perrigo from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Canaccord Genuity Group lowered their target price on Perrigo from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, February 27th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.